These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36890700)

  • 1. Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
    Mooneyhan E; De la Torre Rosas A; Serrano DB; Gamkrelidze I; Sanchez MJ; Kershenobich D; Sereno L; Razavi H
    J Viral Hepat; 2023 Jun; 30(6):551-558. PubMed ID: 36890700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
    Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
    PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Securing sustainable funding for viral hepatitis elimination plans.
    Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
    Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning.
    Trickey A; Hiebert L; Perfect C; Thomas C; El Kaim JL; Vickerman P; Schȕtte C; Hecht R
    Liver Int; 2020 Feb; 40(2):286-297. PubMed ID: 31454466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model of the economic benefits of global hepatitis C elimination: an investment case.
    Scott N; Kuschel C; Pedrana A; Schroeder S; Howell J; Thompson A; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):940-947. PubMed ID: 32730785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
    Kondili LA; Gamkrelidze I; Blach S; Marcellusi A; Galli M; Petta S; Puoti M; Vella S; Razavi H; Craxi A; Mennini FS;
    Liver Int; 2020 Jul; 40(7):1545-1555. PubMed ID: 32078234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of HCV in Russia: Barriers and Perspective.
    Isakov V; Nikityuk D
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
    Scott N; Wilson DP; Thompson AJ; Barnes E; El-Sayed M; Benzaken AS; Drummer HE; Hellard ME
    BMC Med; 2019 Sep; 17(1):175. PubMed ID: 31530275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
    PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation.
    Mooneyhan E; Qureshi H; Mahmood H; Tariq M; Maqbool NA; Anwar M; Aslam M; Azam F; Blach S; Khan AG; Hamid S; Hussain T; Akhter MK; Khan A; Khan U; Khowaja S; Mahmood K; Mazhar S; Nawaz A; Rose A; Ghorezai GSA; Shah S; Sarwar SZ; Razavi H
    J Viral Hepat; 2023 Apr; 30(4):345-354. PubMed ID: 36650932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.